Navigation Links
Essilor: Essilor Forges New Strategic Partnerships Around the World
Date:7/6/2009

PARIS, France, July 7 /PRNewswire-FirstCall/ -- Essilor is pursuing its external growth strategy through a number of recent transactions in Europe, North America and the Middle East.

Essilor has acquired all outstanding shares in De Ceunynck, a major player in the Belgian market where the company is BBGR's long-time distributor. De Ceunynck, which has a prescription laboratory near Antwerp and 92 employees, generated EUR17 million in 2008 revenue. The current management team will remain in place.

In the United States, Essilor is continuing to expand its network with the acquisition of Barnet & Ramel Optical ($10.8 million in revenue), Apex Optical ($2.7 million), ABBA Optical ($2.2 million) and Vision Pointe Optical ($1.1 million). The four prescription laboratories are located respectively in Nebraska, Florida, Georgia and Idaho. Essilor has also acquired a majority stake in OptiSource International ($5.3 million in revenue), a manufacturer and distributor of optical supplies and consumables for opticians and laboratories.

Essilor has joined with Vision Service Plan (VSP) to acquire McLeod Optical, a prescription laboratory based in Rhode Island with 2008 revenue of $10 million. VSP is the largest not-for-profit vision benefits provider in the United States with 55 million members and a network of 26,000 private practice eye doctors. Essilor will have a majority interest and VSP and the principals of McLeod will each own a minority interest in the company.

In the Middle East, Essilor and its partner Amico, the local market-leading distributor of ophthalmic optics products, have signed a contract to set up a 50/50 joint venture that would operate Amico's prescription laboratory in Dubai. The laboratory, which serves the United Arab Emirates, Oman, Qatar and Kuwait, generated 2008 revenue of EUR3.5 million. With the current management team remaining in place, the joint venture will have exclusive distribution rights for the Varilux and Crizal brands in the region and will provide Essilor with a foothold in the Middle East, a market of 265 million people that has significant growth potential.

Lastly, Nikon Optical Canada, a subsidiary of Nikon-Essilor, has signed an agreement to increase from 50% to 100% its stake in TechCite, a prescription laboratory located in Calgary, Alberta. TechCite generated 2008 revenue of approximately C$6.8 million.

Essilor International is the world leader in ophthalmic optical products, offering a wide range of lenses under the flagship Varilux(R), Crizal(R), Essilor(R) and Definity(R) brands to correct myopia, hyperopia, presbyopia and astigmatism. Essilor operates worldwide through 15 production sites, 293 lens finishing laboratories and local distribution networks. The Essilor share trades on the Euronext Paris market and is included in the CAC 40 index. Codes and symbols: ISIN: FR 0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

    Investor Relations and Financial Communications
    Veronique Gillet - Sebastien Leroy
    Phone: +33(0)1-49-77-42-16
   http://www.essilor.com


'/>"/>
SOURCE Essilor
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Essilor: New Acquisitions in the United States and Brazil
2. Essilors 2007 Third-Quarter Report
3. Essilor Cancels 700,000 Shares
4. Essilor : Nomination of Hubert Sagnieres
5. Essilors First-Half 2008 Results
6. Essilor Finalizes Satisloh Agreement
7. Essilor Cancels 1,600,000 Shares
8. Essilor : 2009 First Quarter Report
9. NeoStem Forges Ahead in Its Plan to Open Adult Stem Cell Collection Centers in Key Locations that Can Serve as Hubs to Service Clients Nationwide
10. Micell Forges Strategic Agreement to Develop Advanced Drug-Eluting Stents and Balloons
11. Victoria Forges Global Alliance with Dow AgroSciences for Crop Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)...  Caris Life Sciences, a leading innovator in ... private funder of pancreatic cancer research, are collaborating ... of immunotherapy in the treatment of pancreatic cancer. ... identify potential trial candidates based on biomarker expression ... study investigators. The Lustgarten Foundation is a sponsor ...
(Date:1/17/2017)... Foreside, Maine (PRWEB) , ... January 17, 2017 ... ... announce the addition of Rheumatoid Factor (RF) to its VALIDATE® SP2 calibration verification ... Rheumatoid Factor in a human serum base. Each VALIDATE® SP2 kit is prepared ...
(Date:1/17/2017)... Jan. 17, 2017  An international team of ... and St. Boniface Hospital Albrechtsen Research Centre/University of ... an unmet health need affecting nearly one in ... Clinical Investigation, their results identify small molecule drugs ... reverse neuronal injury in animal models of metabolic, ...
(Date:1/17/2017)... , Jan. 17, 2017   Pulmatrix, Inc . ... company developing innovative inhaled therapies to address serious pulmonary ... fungal infections in the lungs of CF patients, PUR1900, ... (QIDP) by the U.S. Food & Drug Administration. ... designed to speed the development of novel drugs against ...
Breaking Biology Technology:
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic Biomedicals ... el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera ... en 2017, con múltiples sitios previstos a lo largo de Europa ... MSC-1 ... factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa ...
(Date:12/15/2016)... and BADEN-BADEN, Germany , December ... leading global financial services provider, today announced an agreement with ... behavioural biometrics, to join forces. The partnership will enable clients ... strategies in compliance with local data protection regulation. ... In order to ...
(Date:12/15/2016)... Mich. , Dec. 15, 2016  There is ... car doors or starting the engine. Continental will demonstrate ... Las Vegas . Through the combination ... Start and Entry) and biometric elements, the international technology ... of vehicle personalization and authentication. "The integration ...
Breaking Biology News(10 mins):